《大行報告》匯豐研究:中生製藥(01177.HK)收購F-star加強研發管道 評級「買入」
匯豐研究發表研報指,中生製藥(01177.HK)宣布斥資逾1.6億美元收購F-star Therapeutics(FSTX.US),考慮到F-Star在雙特異性抗體領域的專業技術,加上收購作價合理,預期有助中生製藥加強研發管道,在全球化發展中料達到協同效應。
不過由於交易尚未完成,該行未有因此調整業績預測。匯豐研究表示,由於市場情緒復甦,中生製藥的股價自6月以來已回升8%,對比同期恆指升4%,計及公司在手現金及估值吸引,維持對其「買入」評級及目標價7元不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.